Next Generation News and Research

RSS

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses.

16 Jul 2010

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.

16 Jul 2010

Eurofins MWG Operon, Genomatix Software offer joint services to develop complete human exome array

Eurofins MWG Operon, an expert in next generation sequencing and Certified Service Provider for Roche NimbleGen sequence capture, together with Genomatix Software GmbH, a leading company in complex analysis and interpretation of such NGS data, announce that they have developed a complete human exome array, based on Roche NimbleGen sequence capture technology.

15 Jul 2010

First 1M doses of smallpox vaccine for immune-compromised populations delivered

Delivery to the Strategic National Stockpile of the first 1 million doses of the nation's first smallpox vaccine for certain immune-compromised populations is now complete, the result of a Project BioShield contract.

15 Jul 2010

NanoString Technologies increases throughput of nCounter Analysis System

NanoString Technologies, Inc., a privately held life sciences company marketing a novel digital molecular barcoding technology for detecting and counting large sets of targets in biological samples, today announced that it has increased the throughput of its nCounter Analysis System by expanding its multiplexing capacity to 800 gene transcripts per reaction.

From NanoString Technologies 15 Jul 2010

NIH awards $20M grant to support Institute for Clinical & Translational Science efforts

The Institute for Clinical & Translational Science at UC Irvine will get $20 million over five years from the National Institutes of Health to speed the transformation of scientific discoveries into medical advances for patients.

15 Jul 2010

VCU receives $20M NIH grant to join national consortium of research centers

Virginia Commonwealth University announced Wednesday it has received a $20 million grant - the largest federal award in its history - from the National Institutes of Health to become part of a nationwide consortium of research institutions working to turn laboratory discoveries into treatments for patients.

15 Jul 2010

Enrollment complete in Nabi's first NicVAX Phase III clinical trial for nicotine addiction

Nabi Biopharmaceuticals announced today that it has completed enrollment in the first Phase III clinical trial of NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse.

15 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

Researchers awarded $3M grant to establish DC D-CFAR

Researchers from institutions across Washington, DC, led by Alan E. Greenberg, M.D., M.P.H., of The George Washington University School of Public Health and Health Services, have been awarded an approximately $3M grant over five years from the National Institutes of Health to establish the District of Columbia Developmental Center for AIDS Research.

14 Jul 2010

NEB introduces NEBNext Quick DNA Sample Prep Reagent Set 2, Master Mix Set 2

New England Biolabs has expanded its line of reagents for sample preparation with the introduction of NEBNext Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium and GS Junior instruments. These new products provide all the necessary enzymes and buffers for fast fragment library preparation.

From New England Biolabs 14 Jul 2010

Second issue of Novo Nordisk BlueSheet highlights information on diabetes

Novo Nordisk Inc., a global healthcare company and leader in diabetes care, today announced the second issue of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

13 Jul 2010

Syntermed releases NeuroQ version 3.5 for analysis, image display of brain FDG-PET scans

At the Alzheimer's Association 2010 International Conference (ICAD) July 10-14 in Honolulu, HI, Syntermed, Inc. launched NeuroQ™ version 3.5, a nuclear medicine quantitative software platform for analysis and image display of brain FDG-PET scans. NeuroQ can increase physician accuracy in diagnosing and differentiating the many types of dementia, compared to visual interpretation alone of FDG-PET.

12 Jul 2010

Bayer HealthCare announces over $2.5M for largest awards program in hemophilia

Bayer HealthCare announced today that it awarded more than $2.5 million in funding to 19 recipients from 10 countries through its Bayer Hemophilia Awards Program (BHAP). BHAP is the largest awards program of its kind in hemophilia, providing funds that support clinical and basic research, encourage new physicians to enter the field and enable continuing education for caregivers around the world.

12 Jul 2010

Alzheimer's Association launches Internet and phone-based clinical trial matching service

The Alzheimer's Association announced today the launch of Alzheimer's Association TrialMatch(TM), a confidential and free interactive tool that provides comprehensive clinical trial information and an individualized trial matching service for people with Alzheimer's disease and related dementias. The Internet (www.alz.org/trialmatch) and phone-based (800-272-3900) service debuted during the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI.

12 Jul 2010